Latest Breaking News On - மரகதம் உயிர் அறிவியல் இன்க் - Page 1 : comparemela.com

Published: Dec 16, 2020 San Diego, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical biopharmaceutical company focused on developing proprietary molecules with strong clinical and commercial differentiation, announced the publication of a peer-reviewed paper reporting that THCVHS, the Company’s novel THC prodrug, was optimized through a nanoemulsion formulation (THCVHS-NE) for drug delivery into the eye and demonstrated significantly better reduction of intraocular pressure (IOP) compared to the commercially approved standard of care in normotensive rabbits. Response was determined by measuring reduction in IOP from baseline following a single treatment with either THCVHS-NE (1% w/v), latanoprost (0.005% w/v), or timolol (0.25% w/v), which was measured every 30 minutes post-treatment up to 180 minutes, followed by measurements at 240, 360 and 480 minutes post-treatment. Duration of response was

San diegoUnited statesKaram takharPunit dhillonHonors collegeEmerald bioscience incUniversity of mississippiCorporate development investor relationsResearch activityAmerican academy of ophthalmologyTranslational researchDrug deliveryAmerican academyDoctoral universitiesEmerald bioscienceCorporate development